B+
Bull case
20%
Probability
Target price
$110.89
Analysis reference price unavailable
Analysis 2026-02-20 · RankAlpha Sentiment AI
ITGR
IntegerDNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
60%
Probability
Target price
$86.74
Analysis reference price unavailable
Analysis 2026-02-20 · RankAlpha Sentiment AI
B-
Bear case
20%
Probability
Target price
$72.51
Analysis reference price unavailable
Analysis 2026-02-20 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-02-20
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+27.1
Score
AI commentary
Consensus is mixed-to-neutral with median analyst targets near the current price, implying limited near-term upside without positive surprises [#SERP-1]. A smaller set of bullish forecasts creates optionality, but gains are conditional on clear execution and stronger procedure volumes [#SERP-5].
RankAlpha Sentiment AI - 2026-02-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-21catalystNear-term quarterly resultsMedium impact
Next quarterly report will re-test guidance and margins; with analyst targets clustered near the current price, inline results may leave limited upside while misses would push shares lower [#SERP-1][#SERP-4]. Date estimated conservatively.
2026-08-20eventAnalyst revisions / guidanceHigh impact
A round of upgrades or downgrades following guidance could re-rate the stock; outcome-dependent moves could be material given target dispersion [#SERP-1][#SERP-5].
2027-02-20catalystStrategic execution / margin expansionHigh impact
Sustained margin improvement, successful product rollouts, or accretive M&A would justify multiple expansion toward higher analyst targets; failure to execute increases downside risk [#SERP-5][#SERP-6].
Recommendation
N/A
No formal recommendation provided.
As of 2026-02-20 • Updated nightlySource: Internal modelMethodology